Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis.
about
Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalInspiratory muscle training protocol for patients with chronic obstructive pulmonary disease (IMTCO study): a multicentre randomised controlled trial.Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids.Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.Multidimensional analyses to assess the relations between treatment choices by physicians and patients' characteristics: the example of COPD.Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population.Patterns and determinants of COPD-related healthcare utilization by severity of airway obstruction in KoreaReal-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study.The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study.Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD.Adherence to GOLD guideline treatment recommendations among pulmonologists in TurkeyBarriers to guideline-concordant antibiotic use among inpatient physicians: A case vignette qualitative studyQuantitative lung SPECT applied on simulated early COPD and humans with advanced COPD.Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.The unique alterations of hippocampus and cognitive impairment in chronic obstructive pulmonary disease.Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β2-Agonists.Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD.Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities.Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting.Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.Everyday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPD.Focusing a gender lens on emergency medicine research: 2012 update.Adherence to the Global Initiative for Chronic Obstructive Lung Disease guidelines for management of COPD: a hospital-base study.
P2860
Q28074169-2E54AB89-FBE2-42FF-B30D-A686CF845D16Q30450921-14795151-45E2-4ADB-B836-4A68757E8A6EQ33803143-894584C1-231C-49A9-95AB-E052EC0B562EQ34134884-FA767048-44CC-429A-B6DD-39546AE62D18Q34367792-BF4D53BB-E9BA-4915-B9AC-2BFAD3D8BB66Q34826231-E9CF1D29-2BF7-49ED-BBB2-A49D3ADEE48CQ35103337-663D53BD-F07C-42E4-81C1-88B4BFFAA4A3Q35138038-214524E8-4D0C-49D3-B21F-52C761259F6EQ36208427-4139AFB9-1A25-42FE-B74E-18DE4DE7B8E8Q36286968-9890C992-3954-4DCE-AD26-C00D54866CD6Q36303220-10A21424-2C6A-408D-B0F9-C5C1883114B8Q36376413-3000FAB7-5EDB-4DF8-9D33-E62D4E028419Q36390663-6F8E143B-4E0D-4E9A-9473-DA70FA693643Q36654924-0507B1C3-4571-4E57-BCDB-0CD7473B54CFQ36996776-D8905021-C7C2-4CBE-9DF7-606279C71FB5Q37380396-A186F04C-AC6B-43A3-BA2E-8B97A3A365C4Q37390146-FAA2189C-BE04-4CE9-B35C-F8F9A80306BCQ37425324-40F6E5E0-6C28-4B0F-9AF2-F900259A699AQ37675253-D602A6FC-5E0F-4BCB-8662-ED2F44AB6FFFQ38058413-AB912241-6BD4-4B70-B819-CD5DA6FA74A7Q38308933-EB64559D-3DBF-49AC-9E89-186C06E83DCFQ38604621-08BDE5CF-A788-4033-BD1D-C87249783A5BQ38663444-2CA7490C-AC31-410F-B77A-29A2EEDA7689Q42044652-DCFBC847-7B97-48DA-B39C-2830CF467E80Q43520303-C0BBD1A4-D072-469A-9B19-76CC1C2E2ABDQ44450905-0143EF00-FF6E-459A-8F05-5AAA8D3F869FQ44803620-13722B67-2234-4CEA-B417-5616FB16E5B5Q51779715-91634D17-D64A-467F-99D9-F005855260D5
P2860
Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Variation in adherence with Gl ...... ctuarial claims data analysis.
@ast
Variation in adherence with Gl ...... ctuarial claims data analysis.
@en
type
label
Variation in adherence with Gl ...... ctuarial claims data analysis.
@ast
Variation in adherence with Gl ...... ctuarial claims data analysis.
@en
prefLabel
Variation in adherence with Gl ...... ctuarial claims data analysis.
@ast
Variation in adherence with Gl ...... ctuarial claims data analysis.
@en
P2093
P1476
Variation in adherence with Gl ...... ctuarial claims data analysis.
@en
P2093
Bruce Pyenson
Craig Plauschinat
Kathryn Fitch
Kosuke Iwasaki
P304
P356
10.1185/03007995.2011.583230
P407
P577
2011-05-23T00:00:00Z